Insmed (NASDAQ:INSM) Stock Rating Reaffirmed by Cowen

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cowen in a research note issued on Monday, January 6th, reports. They currently have a $56.00 price target on the biopharmaceutical company’s stock. Cowen’s price target indicates a potential upside of 141.07% from the stock’s current price.

Other analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Thursday, October 31st. Morgan Stanley set a $37.00 price objective on shares of Insmed and gave the company a “buy” rating in a research note on Friday, November 1st. Canaccord Genuity started coverage on Insmed in a report on Thursday, January 2nd. They issued a “buy” rating and a $20.00 price target for the company. Credit Suisse Group reiterated an “outperform” rating and issued a $40.00 price target on shares of Insmed in a research report on Thursday, January 2nd. Finally, ValuEngine cut Insmed from a “buy” rating to a “hold” rating in a report on Thursday, December 5th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $37.63.

INSM traded down $0.94 during trading on Monday, hitting $23.23. 61,929 shares of the company traded hands, compared to its average volume of 793,536. The stock’s fifty day moving average is $23.83 and its 200 day moving average is $20.36. The company has a quick ratio of 6.70, a current ratio of 6.97 and a debt-to-equity ratio of 1.19. Insmed has a one year low of $15.33 and a one year high of $33.13. The firm has a market cap of $2.22 billion, a P/E ratio of -5.55 and a beta of 3.04.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The firm had revenue of $38.89 million for the quarter, compared to the consensus estimate of $35.89 million. Insmed had a negative net margin of 291.19% and a negative return on equity of 114.68%. During the same period last year, the company posted ($1.14) earnings per share. On average, equities research analysts forecast that Insmed will post -2.91 EPS for the current fiscal year.

In other news, CAO John Goll sold 25,000 shares of Insmed stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.80, for a total transaction of $520,000.00. Company insiders own 4.95% of the company’s stock.

A number of large investors have recently modified their holdings of INSM. Point72 Hong Kong Ltd purchased a new position in shares of Insmed in the second quarter worth $34,000. Riverhead Capital Management LLC purchased a new stake in shares of Insmed during the 2nd quarter valued at about $73,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Insmed by 17.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,818 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 854 shares during the last quarter. NumerixS Investment Technologies Inc grew its stake in shares of Insmed by 26.5% in the second quarter. NumerixS Investment Technologies Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 1,007 shares during the period. Finally, Tyers Asset Management LLC grew its stake in shares of Insmed by 1,002.5% in the second quarter. Tyers Asset Management LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 6,416 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Story: What causes a stock to be most active?

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with's FREE daily email newsletter.